1
Country: USA | Funding: $614.6M
Neumora Therapeutics develops precision therapies for treatment of brain diseases. Its uses the propriety platform Precision Toolbox, which includes a suite of translational, medical and computational tools for information discovery, capable of applying precision medicine approaches. Its therapeutic portfolio includes seven programs for the treatment of neuropsychiatric disorders and neurodegenerative diseases (major depressive disorder, Alzheimer's disease, schizophrenia, and Parkinson's disease). Neumora's lead program, navacaprant, is a novel, highly selective kappa opioid receptor (KOR) antagonist nearing the end of development as a reliable monotherapy for the treatment of MDD. Navacaprant is an investigational, once-daily oral medication designed to modulate dopamine and reward signaling pathways, which play a critical role in the regulation of mood, cognition, reward and behavior.
Neumora Therapeutics develops precision therapies for treatment of brain diseases. Its uses the propriety platform Precision Toolbox, which includes a suite of translational, medical and computational tools for information discovery, capable of applying precision medicine approaches. Its therapeutic portfolio includes seven programs for the treatment of neuropsychiatric disorders and neurodegenerative diseases (major depressive disorder, Alzheimer's disease, schizophrenia, and Parkinson's disease). Neumora's lead program, navacaprant, is a novel, highly selective kappa opioid receptor (KOR) antagonist nearing the end of development as a reliable monotherapy for the treatment of MDD. Navacaprant is an investigational, once-daily oral medication designed to modulate dopamine and reward signaling pathways, which play a critical role in the regulation of mood, cognition, reward and behavior.
2
Country: USA | Funding: $457.1M
NeuroPace develops and markets implantable devices for the treatment of neurological disorders.
NeuroPace develops and markets implantable devices for the treatment of neurological disorders.
3
Country: USA | Funding: $366.2M
Alzheon is committed to developing innovative medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Our Alzheon’s drug development platform which comprises proprietary chemistries, robust clinical efficacy and safety datasets in patients and genetically-defined subpopulations, and the ability to optimize molecules to have the desired therapeutic attributes.
Alzheon is committed to developing innovative medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Our Alzheon’s drug development platform which comprises proprietary chemistries, robust clinical efficacy and safety datasets in patients and genetically-defined subpopulations, and the ability to optimize molecules to have the desired therapeutic attributes.
4
Country: USA | Funding: $319.5M
Alector is a hypothesis-driven, neurology-focused startup that’s pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. We are combining state-of-the-art antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics that harness the immune system to fight dementia and neurodegeneration.
Alector is a hypothesis-driven, neurology-focused startup that’s pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. We are combining state-of-the-art antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics that harness the immune system to fight dementia and neurodegeneration.
5
Country: USA | Funding: $260M
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases.
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases.
6
Country: UK | Funding: $239.7M
PepGen is empowering nucleic acid therapeutics to go the distance and building neuromuscular and neurologic pipeline.
PepGen is empowering nucleic acid therapeutics to go the distance and building neuromuscular and neurologic pipeline.
7
Country: USA | Funding: $220.5M
Ceribell is focused on making electroencephalography (EEG) widely accessible, more efficient, and more cost-effective
Ceribell is focused on making electroencephalography (EEG) widely accessible, more efficient, and more cost-effective
8
Country: USA | Funding: $181.2M
Skyhawk develops small molecule therapeutics that modulate RNA expression for treatment of cancer, neurological diseases and rare diseases. The company's flagship RNA-targeting drug for Huntington's disease is currently in Phase III clinical trials. Skyhawk's platform consists of: SKYSTAR - system for identifying priority RNA targets, SKYLIBRARY - library of compounds for RNA targets, SKYSEQ - multiplex screening system that simultaneously tests dozens of important targets across various RNA motifs to identify compounds selective for a specific disease target and SKYAI - machine learning model that integrates data from SKYSTAR, medicinal chemistry, animal studies, toxicology studies and clinical programs to develop the next generation of novel RNA splicing modulators.
Skyhawk develops small molecule therapeutics that modulate RNA expression for treatment of cancer, neurological diseases and rare diseases. The company's flagship RNA-targeting drug for Huntington's disease is currently in Phase III clinical trials. Skyhawk's platform consists of: SKYSTAR - system for identifying priority RNA targets, SKYLIBRARY - library of compounds for RNA targets, SKYSEQ - multiplex screening system that simultaneously tests dozens of important targets across various RNA motifs to identify compounds selective for a specific disease target and SKYAI - machine learning model that integrates data from SKYSTAR, medicinal chemistry, animal studies, toxicology studies and clinical programs to develop the next generation of novel RNA splicing modulators.
9
Country: USA | Funding: $180.1M
MicroTransponder is a medical device company that develops and commercializes neurostimulation devices to treat neurological diseases.
MicroTransponder is a medical device company that develops and commercializes neurostimulation devices to treat neurological diseases.
10
Country: USA | Funding: $134.9M
NeuSpera develops implantable medical devices for treating chronic illnesses through minimally invasive solutions.
NeuSpera develops implantable medical devices for treating chronic illnesses through minimally invasive solutions.
11
Country: USA | Funding: $109M
Nido Biosciences develops new precision medicines for neurological diseases and takes aim at Kennedy’s disease, a rare degenerative disorder.
Nido Biosciences develops new precision medicines for neurological diseases and takes aim at Kennedy’s disease, a rare degenerative disorder.
12
Country: USA | Funding: $86.9M
Vaccinex develops novel therapeutic antibodies for treatment of neurodegenerative diseases and cancer. Its drugs are based on the inhibition of semaphorin SEMA4D - potent biological effector believed to prevent immune infiltration and induce myeloid-derived suppressor cells in tumors, as well as trigger neuroinflammation through reactive gliosis in the brain. The company's lead drug candidate, pepinemab, blocks SEMA4D and has the potential to enhance immune activity against tumors and reprogram underlying pathogenic immune mechanisms that exacerbate damage in chronic neurological diseases such as Asheimer's disease and Huntington's disease. The company is also advancing candidates for the treatment of cervical, pancreatic and lung cancer. Vaccinex uses its proprietary ActivMAb drug discovery platform, which enables the discovery and development of highly selective antibodies with novel mechanisms of action against complex membrane proteins.
Vaccinex develops novel therapeutic antibodies for treatment of neurodegenerative diseases and cancer. Its drugs are based on the inhibition of semaphorin SEMA4D - potent biological effector believed to prevent immune infiltration and induce myeloid-derived suppressor cells in tumors, as well as trigger neuroinflammation through reactive gliosis in the brain. The company's lead drug candidate, pepinemab, blocks SEMA4D and has the potential to enhance immune activity against tumors and reprogram underlying pathogenic immune mechanisms that exacerbate damage in chronic neurological diseases such as Asheimer's disease and Huntington's disease. The company is also advancing candidates for the treatment of cervical, pancreatic and lung cancer. Vaccinex uses its proprietary ActivMAb drug discovery platform, which enables the discovery and development of highly selective antibodies with novel mechanisms of action against complex membrane proteins.
13
Country: USA | Funding: $78.2M
We provide neurodegenerative disease patients with expert MDs and 24/7 wrap around care, no matter where you live in the US
We provide neurodegenerative disease patients with expert MDs and 24/7 wrap around care, no matter where you live in the US
14
Country: USA | Funding: $73.7M
Neural Analytics is addressing the global traumatic brain injury epidemic through data science. The company develops robotically assisted ultrasound system for brain health assessment. The company’s technology integrates ultrasound, robotics and machine learning to empower neurologists with critical information about brain health
Neural Analytics is addressing the global traumatic brain injury epidemic through data science. The company develops robotically assisted ultrasound system for brain health assessment. The company’s technology integrates ultrasound, robotics and machine learning to empower neurologists with critical information about brain health
15
Country: UK | Funding: $60M
Aerska develops RNA-based therapies to treat, slow and prevent brain diseases. The company uses blood-brain barrier drug delivery technology to deliver targeted RNA interference-based drugs to treat neurological diseases. This technology serves as a drug delivery platform that transports RNAi across the blood-brain barrier. The technology works by creating antibodies or molecules that bind to specific receptors on the surface of the blood-brain barrier. This action tricks the barrier, allowing the therapeutic agent to pass through endothelial cells and enter the brain parenchyma.
Aerska develops RNA-based therapies to treat, slow and prevent brain diseases. The company uses blood-brain barrier drug delivery technology to deliver targeted RNA interference-based drugs to treat neurological diseases. This technology serves as a drug delivery platform that transports RNAi across the blood-brain barrier. The technology works by creating antibodies or molecules that bind to specific receptors on the surface of the blood-brain barrier. This action tricks the barrier, allowing the therapeutic agent to pass through endothelial cells and enter the brain parenchyma.
16
Country: USA | Funding: $52.5M
Rune Labs is a software and data platform for neuromodulation and brain therapies of the future.
Rune Labs is a software and data platform for neuromodulation and brain therapies of the future.
17
Country: Israel | Funding: $30.5M
Developer of neurology software designed to help patients affected by neurological disorders.
Developer of neurology software designed to help patients affected by neurological disorders.
18
Country: Australia | Funding: AUD$34M
Seer is a medical technology company that specializes in addressing neurological conditions. It created at-home electroencephalograph (EEG) system, Seer Home, which helps providers diagnose epilepsy.
Seer is a medical technology company that specializes in addressing neurological conditions. It created at-home electroencephalograph (EEG) system, Seer Home, which helps providers diagnose epilepsy.
19
Country: Australia | Funding: $20.8M
Global Kinetics Corporation develops movement recording tool for neurologists in the management of Parkinson’s disease.
Global Kinetics Corporation develops movement recording tool for neurologists in the management of Parkinson’s disease.
20
Country: USA | Funding: $14.4M
AgeneBio is developing innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function.
AgeneBio is developing innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function.
21
Country: USA | Funding: $14.2M
Sense Neuro Diagnostics is a developer of non-invasive medical devices for neurological conditions.
Sense Neuro Diagnostics is a developer of non-invasive medical devices for neurological conditions.
22
Country: South Korea | Funding: $13.4M
Through use of technology in which measures and modulates brain signals, we develop research protocols that improve cognitive functions. We provide meaningful information retrieved from the wearable devices through analysis of brain signal big data. With this big data, we predict and diagnose the stages of the neurological diseases such as Alzheimer’s disease and mild cognitive impairment.
Through use of technology in which measures and modulates brain signals, we develop research protocols that improve cognitive functions. We provide meaningful information retrieved from the wearable devices through analysis of brain signal big data. With this big data, we predict and diagnose the stages of the neurological diseases such as Alzheimer’s disease and mild cognitive impairment.
23
Country: Singapore | Funding: $12.3M
Neuroglee Therapeutics is a digital therapeutic platform created to treat patients in the early stages of neurodegenerative disease.
Neuroglee Therapeutics is a digital therapeutic platform created to treat patients in the early stages of neurodegenerative disease.
24
Country: Canada | Funding: $6.8M
Patented, AI-Powered, mobile software, eye tracking technology that captures digital Eye Movement Biomarkers to monitor disease status & progression in neurodegenerative and mental disorders.
Patented, AI-Powered, mobile software, eye tracking technology that captures digital Eye Movement Biomarkers to monitor disease status & progression in neurodegenerative and mental disorders.
25
Country: USA | Funding: $5.5M
CranioSense is developing a non-invasive intracranial pressure monitoring system. It's used to diagnose neurological diseases and monitor patients with traumatic brain injury (which is important in sports and military medicine). The system consists of a forehead patch that attaches two near-infrared optical sensors to the scalp and a portable device (the size of a tablet) for transmitting and processing the information. Special algorithm allows intracranial pressure to be determined in seconds without drilling a hole in the skull or inserting a sensor into the brain.
CranioSense is developing a non-invasive intracranial pressure monitoring system. It's used to diagnose neurological diseases and monitor patients with traumatic brain injury (which is important in sports and military medicine). The system consists of a forehead patch that attaches two near-infrared optical sensors to the scalp and a portable device (the size of a tablet) for transmitting and processing the information. Special algorithm allows intracranial pressure to be determined in seconds without drilling a hole in the skull or inserting a sensor into the brain.
26
Country: Switzerland | Funding: 3
ReHaptix is a clinically validated mHealth application assisting patients and healthcare professionals in monitoring the rehabilitation progress of patients suffering from upper limb impairments caused by a neurological injury, such as stroke, multiple sclerosis or Parkinson's disease.
ReHaptix is a clinically validated mHealth application assisting patients and healthcare professionals in monitoring the rehabilitation progress of patients suffering from upper limb impairments caused by a neurological injury, such as stroke, multiple sclerosis or Parkinson's disease.
27
Country: USA | Funding: $2.6M
dannce.ai uses AI-driven 3D-aligned neural networks to automate behavioral analysis for faster, more accurate drug development and clinical care.
dannce.ai uses AI-driven 3D-aligned neural networks to automate behavioral analysis for faster, more accurate drug development and clinical care.
28
Country: Serbia
NeuroBlast is a sensory device that helps children and adults with neurodegenerative diseases exercise continuously at home, during post-rehabilitation. This simple interactive device incorporates video gamification to encourage users to complete at-home physical therapy in a fun and soothing manner.
NeuroBlast is a sensory device that helps children and adults with neurodegenerative diseases exercise continuously at home, during post-rehabilitation. This simple interactive device incorporates video gamification to encourage users to complete at-home physical therapy in a fun and soothing manner.
29
Country: USA
VistaraBio is applying their proteostasis technologies for target identification in Parkinson's and other neurodegenerative diseases.
VistaraBio is applying their proteostasis technologies for target identification in Parkinson's and other neurodegenerative diseases.
30
Country: Australia
GenieUs Genomics analyses the sequencing data of each patient and turn human biological information into code to treat neurodegenerative diseases.
GenieUs Genomics analyses the sequencing data of each patient and turn human biological information into code to treat neurodegenerative diseases.
32
Country: Germany
Priavoid envisions curing neurological disorders by developing innovative treatment strategies based on a new class of orally available compounds. Focusing on indications with significant unmet medical need Priavoid applies the therapeutic concept to Alzheimer’s disease (AD), neuropathic pain and other neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), tauopathies, Parkinson’s disease (PD), and Huntington’s disease (HD).
Priavoid envisions curing neurological disorders by developing innovative treatment strategies based on a new class of orally available compounds. Focusing on indications with significant unmet medical need Priavoid applies the therapeutic concept to Alzheimer’s disease (AD), neuropathic pain and other neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), tauopathies, Parkinson’s disease (PD), and Huntington’s disease (HD).
